Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Heart Failure × pertuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 68 Neoplasms 5 HER2-positive Breast Cancer 5 Carcinoma, Non-Small-Cell Lung 4 Triple Negative Breast Neoplasms 3 Prostatic Neoplasms 3 Ovarian Neoplasms 3 Neoplasm Metastasis 3 Stomach Neoplasms 2 Pathologic Complete Response 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Locally Advanced Breast Cancer 2 Biliary Tract Neoplasms 2 Anatomic Stage I Breast Cancer AJCC v8 2 Urinary Bladder Neoplasms 1 Salivary Gland Neoplasms 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Neuroendocrine Tumors 1 Neuroblastoma 1 Neoplastic Cells, Circulating 1 Multiple Endocrine Neoplasia 1 Metastatic HER2-Positive Breast Cancer 1 Metastatic Breast Cancer With a Isolated Brain Progression 1 Malignant Solid Neoplasm 1 Lung Neoplasms 1 Inflammatory Breast Neoplasms 1 Her2-Positive Breast Cancer 1 Hemangiosarcoma 1

Interventions

Control Groups 2 Atorvastatin 2 pertuzumab 1 nicotinamide-beta-riboside 1 empagliflozin 1 dapagliflozin 1 candesartan 1 Trastuzumab 1 Sodium Chloride 1 Simendan 1 Pyruvic Acid 1 Population Groups 1 Ogivri 1 Metoprolol 1 Hydroxymethylglutaryl-CoA Reductase Inhibitors 1 Eplerenone 1 Carvedilol 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04680442 2025-04-06

SCHOLAR-2

Population Health Research Institute

Phase 2 Recruiting

Breast Neoplasms, Heart Failure

Data powered by HemOnc (CC BY 4.0) Colophon ⚡